Amgen has signed an outcome-based refund contract with Harvard Pilgrim for Repatha.
The terms of the agreement state that if a patient who is taking Repatha suffers a heart attack or stroke while on the medication, Harvard Pilgrim will receive a rebate for the cost of the medication.
The announcement was made from the World Medical Innovation Forum, and the agreement is aimed at giving an extra measure of confidence to both the companies involved in the agreement and the patients prescribed Repatha.
"That Amgen is willing to go at financial risk for patients with elevated LDL-C levels who are adherent to Repatha and suffer cardiovascular events shows that they are willing to stand by their data, and that sends a strong positive message to health plans, prescribing physicians and patients," Michael Sherman, chief medical officer at Harvard Pilgrim, said.
Repatha functions by inhibiting PCSK9 and effectively increasing the necessary LDLRs and lowering LDL-C values.
Alerts Sign-up